Loading...
Loading...
Browse all stories on DeepNewz
VisitMedicare to Cover Eli Lilly's Zepbound for Sleep Apnea Following FDA Approval
Jan 8, 2025, 08:34 PM
The Centers for Medicare & Medicaid Services (CMS) has announced that Medicare will cover Eli Lilly's Zepbound for the treatment of obstructive sleep apnea (OSA). This decision follows the drug's recent FDA approval, making Zepbound the first medication specifically approved for moderate-to-severe OSA. The coverage under Medicare Part D is expected to enhance the drug's market potential, as it is already recognized as a significant treatment option for obesity-related conditions.
View original story
Markets
No • 50%
Yes • 50%
Official announcements from major insurance companies
Yes • 50%
No • 50%
Eli Lilly's financial reports and statements
No • 50%
Yes • 50%
FDA announcements and press releases
200,000 to 300,000 • 25%
More than 300,000 • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
Pharmaceutical prescription data and reports
Stock price increases by 10% to 15% • 25%
Stock price increases by less than 5% • 25%
Stock price increases by more than 15% • 25%
Stock price increases by 5% to 10% • 25%
Stock market data and financial analysis reports
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Market research reports and industry analyses